In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • Whenever we needed them they were there. Whenever we needed new information or help finding a new treatment they were there immediately. They were such a pleasure to deal with that they were like a family member helping you out, and believe me I/we needed them. 

    Dr. Mel Burchman
    Spouse of a pancreatic cancer patient
  • Whether via email or phone, I found the representative polite, professional, courteous, and knowledgeable. And I like that they reached out to my oncologist.

    Donald
    Pancreatic cancer patient

  • Cancer Commons is extremely engaged and proactive. Its professionals have directed us towards interesting avenues to explore in our search for additional treatment options.

    Mark Bezner
    Husband of stage IV ovarian cancer patient

  • The team at Cancer Commons created a very thorough and clear report which is extremely helpful! It is evident they took the time to read my father’s medical history and suggest a personalized plan for his condition. Matt was extremely kind and supportive during this difficult time. Thank you!

    Gali
    Daughter of a glioblastoma patient

  • Emma Shtivelman is the best—bar none.

    Linda King-Byrnes

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.